Market Newsdesk

Baxter BioPharma Solutions Announces $50 Million Investment to Expand Sterile Fill/Finish Manufacturing Site in Bloomington, Ind.

• Construction currently underway; expected to be completed in 2021
• Expanded facilities expected to support approximately 100 new jobs locally

DEERFIELD, Ill.–(BUSINESS WIRE)–
Baxter International Inc. (NYSE:BAX), a global leader in sterile medication production and delivery, today announced a $50 million expansion of its sterile fill/finish manufacturing facilities located in Bloomington, Ind. These facilities are operated by Baxter’s BioPharma Solutions business, a premier contract manufacturing organization that specializes in parenteral (injectable) pharmaceuticals. The expansion is being funded by a combination of Baxter and client investment. Additional details of the agreement were not disclosed.

The planned expansion of existing facility infrastructure includes construction of a new 25,000 square foot warehouse; a new filling line for flexible plastic containers; a high-speed automated syringe fill line capable of filling up to 600 units per minute and a new high-speed automated visual inspection line. Construction is currently underway and is expected to be completed in 2021. Contract product manufacturing in the expanded facilities is expected to begin in 2022. The new facilities will support programs that are expected to add approximately 100 new jobs at the site, in addition to jobs created due to construction.

“We pride ourselves on being a contract manufacturing partner with the specialized expertise, proven experience, and facilities to help our clients successfully achieve their sterile manufacturing objectives,” said Marie Keeley, vice president, BioPharma Solutions. “Our Bloomington facility is already a global leader in sterile contract manufacturing, and this expansion will add capacity and state-of-the-art technology that will better enable us to meet the diverse needs of our clients and the patients they serve.”

The Bloomington site currently manufactures life-saving products for approximately 25 pharmaceutical and biotechnology companies. The site has capabilities and expertise in parenteral delivery systems and clinical and commercial vaccine manufacturing, including preventive and seasonal vaccines for global markets. In addition, Bloomington offers a range of production and commercialization services, including clinical development, formulation, packaging and commercial launch capabilities. The site is also home to the Lyophilization Center of Excellence, an industry-leading resource center focused on the development of high-quality freeze drying.

About Baxter BioPharma Solutions

Together with its sister contract manufacturing facility in Halle (Westfalen) Germany, Baxter BioPharma Solutions offers services for prefilled syringes, liquid and lyophilized vials and cartridge filling as well as specialized capabilities for cytotoxics and biologics manufacturing. For more information on BioPharma Solutions, visit: www.BaxterBioPharmaSolutions.com.

About Baxter

Every day, millions of patients and caregivers rely on Baxter’s leading portfolio of critical care, nutrition, renal, hospital and surgical products. For more than 85 years, we’ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers that make it happen. With products, technologies and therapies available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit www.baxter.com and follow us on Twitter, LinkedIn and Facebook.

This release includes forward-looking statements concerning Baxter BioPharma Solutions, including the proposed investment in the expansion of its facilities. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: the company’s ability to finance and develop new products or enhancements; satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; product quality, manufacturing or supply, or patient safety issues; changes in law and regulations; and other risks identified in Baxter’s most recent filing on Form 10-K and other SEC filings, all of which are available on Baxter’s website. Baxter does not undertake to update its forward-looking statements.

Baxter is a registered trademark and BioPharma Solutions is a trademark of Baxter International Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201124005593/en/

Media Contact

Eric Tatro, (224) 948-5353

[email protected]

Investor Contact

Clare Trachtman, (224) 948-3020

KEYWORDS: Indiana Illinois United States North America

INDUSTRY KEYWORDS: Biotechnology Other Manufacturing Medical Supplies Health Medical Devices Logistics/Supply Chain Management Transport Manufacturing

MEDIA:

Logo

Western Asset Inflation-Linked Income Fund Announces Plan for Tender Offer

NEW YORK–(BUSINESS WIRE)–
Western Asset Inflation-Linked Income Fund (NYSE: WIA) announced today that the Fund’s Board of Trustees has authorized (subject to certain conditions) a cash tender offer for up to 20% of the Fund’s outstanding common shares (the “Shares”) at a price per Share equal to 99% of the Fund’s net asset value per Share as of the business day immediately following the expiration date of the tender offer. The commencement of the tender offer will be announced at a later date. The Fund will repurchase Shares tendered and accepted in the tender offer in exchange for cash. In the event the tender offer is oversubscribed, Shares will be repurchased on a pro rata basis.

The commencement of the tender offer is pursuant to an agreement (the “Standstill Agreement”) between the Fund and Karpus Investment Management (“Karpus”). During the effective period of the Standstill Agreement, Karpus has agreed to (1) be bound by the terms of the Standstill Agreement, including certain standstill covenants, and (2) vote its Shares on proposals submitted to shareholders in accordance with the recommendation of the Fund’s Board of Trustees (subject to certain limited exclusions). The Fund has been advised that Karpus will file a copy of the Standstill Agreement with the U.S. Securities and Exchange Commission (“SEC”) as an exhibit to its Schedule 13D.

The Fund has not commenced the tender offer described in this release. This announcement is not a recommendation, an offer to purchase or a solicitation of an offer to sell shares of the Fund and the above statements are not intended to constitute an offer to participate in any tender offer. Information about the tender offer, including its commencement, will be provided by future public announcements. Shareholders will be notified in accordance with the requirements of the Securities Exchange Act of 1934, as amended, and the Investment Company Act of 1940, as amended, either by publication or mailing or both. The tender offer will be made only by an offer to purchase, a related letter of transmittal, and other documents to be filed with the SEC. Shareholders of the Fund should read the offer to purchase and tender offer statement and related exhibits when those documents are filed and become available, as they will contain important information about the tender offer. These and other filed documents will be available to investors for free both at the website of the SEC and from the Fund. There can be no assurance that any Share repurchases will reduce or eliminate the discount of the Fund’s market price per Share to the Fund’s net asset value per Share.

Western Asset Inflation-Linked Income Fund, a diversified, closed-end management investment company, is administered by Legg Mason Partners Fund Advisor, LLC (“LMPFA”), is advised by Western Asset Management Company, LLC (“Western Asset”) and is subadvised by Western Asset Management Company Limited (“Western London”), Western Asset Management Company Ltd (“Western Japan”) and Western Asset Management Company Pte. Ltd. (“Western Asset Singapore”). Each of LMPFA, Western Asset, Western London, Western Japan and Western Singapore is an indirect, wholly-owned subsidiary of Franklin Resources, Inc.

This press release may contain statements regarding plans and expectations for the future that constitute forward-looking statements within the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on the Fund’s current plans and expectations, and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Additional information concerning such risks and uncertainties are contained in the Fund’s filings with the SEC.

For more information about the Fund, please call Investor Relations: 1-888-777-0102, or consult the Fund’s web site at www.lmcef.com. The information contained on the Fund’s web site is not part of this press release. Hard copies of the Fund’s complete audited financial statements are available free of charge upon request.

Category: Fund Announcement

Source: Franklin Templeton

View source version on businesswire.com: https://www.businesswire.com/news/home/20201124005493/en/

Media Contact: Fund Investor Services-1-888-777-0102

 

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Posted on November 24, 2020 8:03 am

bluebird bio Announces Live Webcast to Review Clinical Data Presented at the American Society of Hematology (ASH) Annual Meeting

bluebird bio Announces Live Webcast to Review Clinical Data Presented at the American Society of Hematology (ASH) Annual Meeting

CAMBRIDGE, Mass.–(BUSINESS WIRE)–bluebird bio, Inc. (Nasdaq: BLUE) today announced that the company will host a live webcast on December 7, 2020 at 7:00 p.m. ET to review clinical data presented at the 62^nd American Society of Hematology Annual Meeting and Exposition.

Investors may listen to the call by dialing (844) 825-4408 from locations in the United States or +1 (315) 625-3227 from outside the United States. Please refer to conference ID number 3493595.

To access the live webcast of bluebird bio’s presentation, please visit the “Events & Presentations” page within the Investors & Media section of the bluebird bio website at http://investor.bluebirdbio.com. Replays of the webcast will be available on the bluebird bio website for 90 days following the event.

About bluebird bio, Inc.

bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, we’re developing gene therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond our labs, we’re working to positively disrupt the healthcare system to create access, transparency and education so that gene therapy can become available to all those who can benefit.

bluebird bio is a human company powered by human stories. We’re putting our care and expertise to work across a spectrum of disorders including cerebral adrenoleukodystrophy, sickle cell disease, β-thalassemia and multiple myeloma, using three gene therapy technologies: gene addition, cell therapy and (megaTAL-enabled) gene editing.

bluebird bio has additional nests in Seattle, Wash.; Durham, N.C.; and Zug, Switzerland. For more information, visit bluebirdbio.com.

Follow bluebird bio on social media: @bluebirdbio, LinkedIn, Instagram and YouTube.

bluebird bio is a trademark of bluebird bio, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201124005587/en/

Investors & Media

Investors:

Ingrid Goldberg, 857-217-0490

[email protected]

OR

Elizabeth Pingpank, 617-914-8736

[email protected]

Media:

Jenn Snyder, 617-448-0281

[email protected]

KEYWORDS: Massachusetts United States North America Canada

INDUSTRY KEYWORDS: Biotechnology Health Genetics Pharmaceutical Clinical Trials

MEDIA:

Logo

Splunk to Acquire Network Performance Monitoring Leader Flowmill

Acquisition to Extend the Power of Splunk’s Industry-Leading Observability Platform

SAN FRANCISCO–(BUSINESS WIRE)–Splunk Inc. (NASDAQ: SPLK), provider of the Data-to-Everything Platform, today announced it has signed a definitive agreement to acquire Flowmill, a Palo-Alto based cloud network observability company with expertise in network performance monitoring (NPM). The acquisition is expected to close during Splunk’s fiscal fourth quarter, subject to customary closing conditions.

With this acquisition, Splunk will continue to deliver on its vision to offer the world’s most comprehensive Observability Suite. With Flowmill, Splunk further expands its existing observability capabilities, giving customers the ability to ingest, analyze and take action on additional cloud network and infrastructure data to quickly resolve network-related issues, optimize network performance and reduce network costs.

“Observability technology is rapidly increasing in both sophistication and ability to help organizations revolutionize how they monitor their infrastructure and applications. Flowmill’s innovative NPM solution provides real-time observability into network behavior and performance of distributed cloud applications, leveraging extended Berkeley Packet Filter (eBPF) technologies,” said Tim Tully, chief technology officer, Splunk. “We’re excited to bring Flowmill’s visionary NPM technology into our Observability Suite as Splunk continues to deliver best-in-class observability capabilities to our customers.”

eBPF is a valuable, underutilized data source that is encountered in all cloud-native use cases and much easier to access than traditional networking data. eBPF is a critical component for full-stack observability. It enables broad visibility into interactions between applications, networks and other infrastructure elements. In order to leverage eBPF, systems must be equipped to efficiently collect, integrate, and store high data volumes produced by a large distribution system.

“Flowmill’s approach to building systems that support full-fidelity, real-time, high-cardinality ingestions and analysis aligns well with Splunk’s vision for observability,” said Jonathan Perry, founder and CEO, Flowmill. “We’re thrilled to join Splunk and bring eBPF, next-generation NPM to the Splunk Observability Suite.”

Flowmill will complement Splunk’s recent acquisitions of Plumbr and Rigor, giving customers the ability to address every application performance monitoring (APM), digital enterprise monitoring (DEM) and NPM need across all types of applications and infrastructures. For additional information on Splunk’s industry-leading Observability portfolio, visit the Splunk website.

Safe Harbor Statement

This press release contains forward-looking statements that involve risks and uncertainties, including statements regarding the expected benefits of the acquisition of Flowmill, the impact of the acquisition on Splunk’s existing and future products and services, and the capabilities of Flowmill’s products and services, including when combined with Splunk’s. There are a significant number of factors that could cause actual results to differ materially from statements made in this press release, including: difficulties encountered in closing and integrating the merged business, technologies, personnel and operations; costs related to the acquisition; market acceptance of the acquisition and resulting products and services; Splunk’s inability to realize value from its significant investments in its business, including product and service innovations; and general market, political, economic and business conditions.

Additional information on potential factors that could affect Splunk’s financial results is included in the company’s Quarterly Report on Form 10-Q for the quarter ended July 31, 2020, which is on file with the U.S. Securities and Exchange Commission. Splunk does not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made.

About Splunk Inc.

Splunk Inc. (NASDAQ: SPLK) turns data into doing with the Data-to-Everything Platform. Splunk technology is designed to investigate, monitor, analyze and act on data at any scale.

Splunk, Splunk>, Data-to-Everything, D2E and Turn Data Into Doing are trademarks and registered trademarks of Splunk Inc. in the United States and other countries. All other brand names, product names, or trademarks belong to their respective owners. © 2020 Splunk Inc. All rights reserved.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201124005443/en/

Media Contact

Richard Brewer-Hay

Splunk Inc.

[email protected]

Investor Contact

Ken Tinsley

Splunk Inc.

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Data Management Security Technology Software Networks Internet

MEDIA:

Posted on November 24, 2020 8:03 am

Twist Bioscience to Present at Upcoming Virtual Investor Conferences

Twist Bioscience to Present at Upcoming Virtual Investor Conferences

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Bioscience, will present at the following upcoming virtual investor conferences:

• Piper Sandler 32nd Annual Virtual Healthcare Conference, recorded fireside chat available at 8:00 a.m. ET on Monday, November 30
• 2020 Evercore ISI HealthCONx Conference on Tuesday, December 1 at 1:50 p.m. ET

Both presentations can be accessed by visiting the “Investor Calendar” page of the investor relations section of the company’s website here. A replay of the presentations will be archived for a period of 90 days following the conclusion of the live event.

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Follow us on Twitter | Facebook | LinkedIn | YouTube

View source version on businesswire.com: https://www.businesswire.com/news/home/20201124005405/en/

Investor Contact:

Argot Partners

Maeve Conneighton

212-600-1902

[email protected]

Media Contact:

Angela Bitting

925-202-6211

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Technology Research Genetics Nanotechnology Biotechnology Health Pharmaceutical Other Science Science

MEDIA:

Logo

IPR Center, Amazon Launch ‘Operation Fulfilled Action’ to Stop Counterfeits

WASHINGTON–(BUSINESS WIRE)–
The U.S. government’s National Intellectual Property Rights Coordination Center (IPR Center) and Amazon today announced the launch of a joint operation to prevent counterfeit goods from entering the U.S. and help protect American consumers. U.S. Customs and Border Protection (CBP) and DHL are also supporting the operation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201124005382/en/

“The IPR Center plays a critical role in securing the global supply-chain to protect the health and safety of the American public,” said IPR Center Director Steve Francis. “However, our efforts are increased with partners like Amazon to identify, interdict, and investigate individuals, companies, and criminal organizations engaging in the illegal importation of counterfeit products. This joint operation is our latest public-private initiative bringing us one step closer to border security.”

“Amazon conducts investigations and sidelines inventory if we suspect a product may be counterfeit, ensuring our customers are protected,” said Dharmesh Mehta, vice president, Customer Trust and Partner Support, Amazon. “But we also know that counterfeiters don’t just attempt to offer their wares in one store, they attempt to offer them in multiple places. Now, by combining intelligence from Amazon, the IPR Center, and other agencies, we’re able to stop counterfeits at the border, regardless of where bad actors were intending to offer them. We appreciate the partnership from the IPR Center and other agencies to protect American consumers and prosecute bad actors.”

In an effort to protect consumers, this joint operation will analyze data and conduct targeted inspections aimed at preventing counterfeit products from entering the U.S. supply chain. The IPR Center and Amazon will leverage evidence obtained during the operation to expand on-going investigations, with the goal of holding bad actors accountable to the fullest extent of the law.

This operation will be led by Amazon’s Counterfeit Crimes Unit, which was created earlier this year to support law enforcement investigations and to initiate civil litigation against counterfeiters.

Amazon strictly prohibits the sale of counterfeit products, and in 2019 alone, invested more than $500 million to protect its store and customers from counterfeit and other forms of fraud and abuse. These investments include machine learning and automated systems to detect bad actors and potentially counterfeit products, dedicated teams to operate and continually refine its anti-counterfeiting programs, and tools that help Amazon work with and empower brands. As a result, 99.9% of pages viewed by customers on Amazon did not receive a valid counterfeit complaint and customers continue to shop with confidence on Amazon.

This operation builds on longstanding strategic public-private initiatives currently in place at the IPR Center. Amazon proactively provides the IPR Center with data on confirmed counterfeiters to assist with investigative efforts to stop crime. More recently in May, Amazon was one of six industry leaders to join the IPR Center in an unprecedented public-private partnership to combat fraud and other illegal activity related to COVID-19 through Operation Stolen Promise (OSP). OSP is a joint task force focused on combating COVID-19 related fraud and criminal activity.

The IPR Center is one of the U.S. government’s key weapons in the fight against criminal counterfeiting and piracy. The center uses the expertise of 25 key federal and international agencies to share information, develop initiatives, coordinate enforcement actions, and conduct investigations related to IP theft and commercial fraud crimes.

About National Intellectual Property Rights Coordination Center

The National Intellectual Property Rights Coordination Center, working collaboratively with its public and private sector partners, stands at the forefront of the United States government’s response to combatting global intellectual property theft and enforcing intellectual properties rights violations. The IPR Center was established to combat global intellectual property theft – and, accordingly, has a significant role policing the sale and distribution of counterfeit goods on websites, social media, and the dark web. To report IP theft or to learn more about the IPR Center, visit www.IPRCenter.gov.

About Amazon

Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. Customer reviews, 1-Click shopping, personalized recommendations, Prime, Fulfillment by Amazon, AWS, Kindle Direct Publishing, Kindle, Fire tablets, Fire TV, Amazon Echo, and Alexa are some of the products and services pioneered by Amazon. For more information, visit amazon.com/about and follow @AmazonNews.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201124005382/en/

Amazon.com, Inc.

Media Hotline

[email protected]

www.amazon.com/pr

KEYWORDS: United States North America District of Columbia

INDUSTRY KEYWORDS: Supply Chain Management Online Retail Law Enforcement/Emergency Services Retail Public Policy/Government

MEDIA:

Logo

Logo

Wizard Brands, Inc. Appoints Scott D. Kaufman Chairman and Chief Executive Officer and Heidi C. Bowman as CFO; Mike Rees Appointed CEO of Jevo Holdings, LLC; Peter Katz Appointed President Of Wizard Special Events, LLC

LOS ANGELES–(BUSINESS WIRE)–
Wizard Brands, Inc. (OTCBB WIZD) today announced the appointment of Scott Kaufman as Chairman and Chief Executive Officer. The Company also announced that finance and accounting executive Heidi C. Bowman has been appointed CFO for Wizard Brands, Inc. and distribution executive Mike Rees will take over as CEO of Jevo Holdings, LLC, a wholly-owned subsidiary of Wizard Brands, Inc..

“Scott Kaufman brings to Wizard Brands his solid business experience and proven success in corporate finance and strategic operational and financial development. With Scott’s experienced leadership and knowledge in guiding companies on the path to financial success, Wizard Brands is poised to expand its already significant footprint. Scott will work with us to guide the company through its next phase of growth and beyond. Mike Rees, with his years of operating experience as a distributor, will expertly guide the Jevo unit,” said Paul Kessler, Chairman of the Wizard Brands Board of Directors.

Jevo Holdings, LLC, a wholly-owned subsidiary of Wizard Brands, Inc. will be overseen by CEO Michael R. Rees, who has spent the better part of his career in the private business sector launching and building innovative companies with extensive experience in distribution. Mr. Rees’ expertise includes creating and managing distributorships and the managing and training of sales and marketing teams.

Jevo Holdings, LLC manufactures, markets and distributes the patented ‘JEVO’ Automated Gelatin Shot Maker for various applications in the hospitality, skilled nursing, pharmaceuticals, health, and cannabis segments. A consumer unit of the ‘Jevo’ machine is in the initial phases of research and development.

Wizard Special Events LLC, a wholly-owned subsidiary of Wizard Brands, Inc., operates Wizard World Virtual, Wizard World Vault, and Wizard World pop culture festivals. Peter Katz has been named President, and Joseph Avino has been named Executive Vice President, of Wizard Special Events, LLC. Both Mr. Katz and Mr. Avino are experienced long-tenured executives in the exhibition industry.

Scott D. Kaufman, currently an Independent Director at Wizard Brands, Inc., and a founding member of Barlock Capital Management LLC and Hillair Capital Management LLC, will continue his role at Bristol Capital Advisors in the capacity of Institutional Investor in Residency. Mr. Kaufman has over twenty years of experience investing in private and public companies, trading securities and managing investment portfolios. Mr. Kaufman received his undergraduate degree from Columbia University and an MBA from Columbia University.

Joining Mr. Kaufman in the executive management of Wizard Brands, Inc. is Heidi C. Bowman, who has been appointed as CFO. Ms. Bowman brings with over 30 years of finance and accounting experience in a variety of industries including private equity, oil & gas and real estate. Ms. Bowman received her undergraduate degree from UCLA in Economics.

Wizard Brands, Inc., is a dynamic and multi-faceted holding company comprised of growing brands, led by a management team with proven success and experience tasked with the execution of a twofold strategy: (i) continue to execute on the business plan of the wholly-owned operating companies while growing and enhancing its business operations and financial position, (ii) pursue opportunities to acquire complementary businesses that will create value for Wizard Brands customer base and stakeholders. Current Executive Chairman Paul Kessler and current CEO John D. Maatta will remain as members of the Wizard Brands, Inc. Board of Directors. The appointments of Mr. Kaufman, Ms. Bowman, Mr. Rees and Mr. Katz and Mr. Avino are effective as of November 24, 2020.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201124005346/en/

Jerry Milani

[email protected]

646-883-5022

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Professional Services Entertainment Other Professional Services Other Entertainment General Entertainment Finance Accounting

MEDIA:

Logo

Legend Biotech to Host Virtual Investor KOL Event Reviewing Latest CARTITUDE-1 Data from the 62^nd American Society of Hematology (ASH) Annual Meeting

SOMERSET, N.J.–(BUSINESS WIRE)–
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech) today announced that it will host a virtual Key Opinion Leader (KOL) event on Monday, December 7 at 7 pm ET highlighting the latest data from the Phase 1b/2 CARTITUDE-1 study (NCT03548207) of ciltacabtagene autoleucel (cilta-cel), an investigational BCMA-directed CAR-T cell therapy being studied for the treatment of patients with relapsed or refractory multiple myeloma. This will follow the oral presentation of the study results (Abstract #177) at the 2020 ASH Annual Meeting.

Intended for investors and other interested audiences, the event includes presentations by Ying Huang, PhD, CEO and CFO of Legend Biotech, along with the following leading professionals in hematology and oncology:

• Sundar Jagannath, MD, Professor of Medicine, Hematology and Medical Oncology, Mount Sinai School of Medicine; Director, Multiple Myeloma Program at Mount Sinai Hospital.
• Thomas G. Martin, MD, Clinical Professor of Medicine, Adult Leukemia and Bone Marrow Transplantation Program, and Associate Director, Myeloma Program, UCSF; Co-Leader, Hematopoietic Malignancies Program, Helen Diller Family Comprehensive Cancer Center.

To register and to view the live webcast, please visit: LegendBiotechASH2020.Convene.com.

About CARTITUDE-1

Cilta-cel is currently being investigated in the Phase 1b/2 CARTITUDE-1 (MMY2001, NCT03548207) registration study conducted in the US and Japan for the treatment of patients with multiple myeloma who have received at least 3 prior lines of therapy or are double refractory to a PI and IMiD^®, received a PI, an IMiD, and anti-CD38 antibody and documented disease progression within 12 months of starting the most recent therapy.

About Cilta-cel

Cilta-cel is an investigational chimeric antigen receptor T (CAR-T) cell therapy, formerly identified as JNJ-4528 in the U.S. and Europe and LCAR-B38M in China, that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and in earlier lines of treatment. The design consists of a structurally differentiated CAR-T with two BCMA-targeting single domain antibodies. In December 2017, Legend Biotech, Inc. entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, Inc. (Janssen) to develop and commercialize cilta-cel. In addition to a Breakthrough Therapy Designation (BTD) granted in the U.S. in December 2019, cilta-cel received a PRIority MEdicines (PRiME) designation from the European Commission in April 2019 and BTD in China in August 2020. In addition, Orphan Drug Designation was granted for cilta-cel by the U.S. FDA in February 2019, and by the European Commission in February 2020.

About Legend Biotech

Legend Biotech is a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications. Our team of over 800 employees across the United States, China and Europe, along with our differentiated technology, global development, and manufacturing strategies and expertise, provide us with the strong potential to discover, develop, and manufacture cutting-edge cell therapies for patients in need. We are engaged in a strategic collaboration to develop and commercialize our lead product candidate, ciltacabtagene autoleucel, an investigational BCMA targeted CAR-T cell therapy for patients with multiple myeloma. This candidate is currently being studied in registrational clinical trials. To learn more about Legend Biotech, visit us on LinkedIn, or on Twitter @LegendBiotech or at www.legendbiotech.com.

Cautions Concerning Forward-Looking Statements

This information constitutes forward-looking statements relating to the business of Legend, including express or implied discussions regarding the clinical development of its product candidates and potential attributes and benefits of such product candidates. Such forward-looking statements reflect the current views of Legend’s management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, Legend’s expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays or government regulation generally; Legend’s ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing and other political pressures. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.

The safety and efficacy of the product candidates and/or uses under investigation have not been established. There is no guarantee that the product candidates will receive health authority approval or become commercially available in any country for the uses being investigated.

The information in this press release speaks only as of the date hereof. Legend assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information on this page as current or accurate after its publication date.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201124005327/en/

For Media and Investor Relations inquiries, please contact:

Jessie Yeung, Head of Corporate Finance and Investor Relations, Legend Biotech

[email protected] or [email protected]

Surabhi Verma, Manager of Investor Relations and Corporate Communications, Legend Biotech

[email protected] or [email protected]

For Medical Affairs inquiries, please contact:

Tonia Nesheiwat, Executive Director, Medical Affairs, Legend Biotech

[email protected] or [email protected]

KEYWORDS: New Jersey United States North America

INDUSTRY KEYWORDS: Oncology Health Hospitals Clinical Trials Pharmaceutical Biotechnology

MEDIA:

Logo

Guidewire Software to Announce First Quarter Fiscal 2021 Financial Results on December 8, 2020

SAN MATEO, Calif.–(BUSINESS WIRE)–
Guidewire Software, Inc. (NYSE: GWRE), the platform Property & Casualty (P&C) insurers trust to engage, innovate, and grow efficiently, today announced that it will release its financial results for the fiscal quarter ended October 31, 2020 after market close on Tuesday, December 8, 2020. On that day, management will hold a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to review and discuss the Company’s results for the first quarter 2021. A recorded version of this webcast will be available two hours after the call and accessible at http://ir.guidewire.com.

What:			Guidewire Software First Quarter Fiscal 2021 Financial Results Conference Call
When:			Tuesday, December 8, 2020
Time:			2:00 p.m. PT (5:00 p.m. ET)
Live Call:			(877) 705-6003, Domestic
			(201) 493-6725, International
Replay:			(844) 512-2921, Passcode 13713614, Domestic
			(412) 317-6671, Passcode 13713614, International
Webcast:			http://ir.guidewire.com/ (live and replay)

The webcast will be archived on Guidewire’s website for a period of three months.

About Guidewire Software

Guidewire is the platform P&C insurers trust to engage, innovate, and grow efficiently. We combine digital, core, analytics, and AI to deliver our platform as a cloud service. More than 400 insurers, from new ventures to the largest and most complex in the world, run on Guidewire.

As a partner to our customers, we continually evolve to enable their success. We are proud of our unparalleled implementation track record, with 1,000+ successful projects, supported by the largest R&D team and partner ecosystem in the industry. Our marketplace provides hundreds of applications that accelerate integration, localization, and innovation.

For more information, please visitwww.guidewire.com and follow us on twitter: @Guidewire_PandC.

NOTE: For information about Guidewire’s trademarks, visit https://www.guidewire.com/legal-notices.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201124005323/en/

Investor Relations Contact:

Garo Toomajanian

ICR, LLC

+1 (650) 357 5282

[email protected]

Media Contact:

Diana Stott

Guidewire Software, Inc.

+1 (650) 356 4941

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Data Management Professional Services Technology Insurance Software

MEDIA: